Prevalence, Characteristics, Management, and Outcomes of Difficult-to-Treat Inflammatory Bowel Disease - Top-Institutions - MDSpire

Prevalence, Characteristics, Management, and Outcomes of Difficult-to-Treat Inflammatory Bowel Disease

  • By

  • Tommaso Lorenzo Parigi

  • Luca Massimino

  • Alfredo Carini

  • Roberto Gabbiadini

  • Peter Bertoli

  • Mariangela Allocca

  • Cristina Bezzio

  • Arianna Dal Buono

  • Ferdinando D’Amico

  • Federica Furfaro

  • Laura Loy

  • Alessandra Zilli

  • Federica Ungaro

  • Vipul Jairath

  • Laurent Peyrin-Biroulet

  • Alessandro Armuzzi

  • Silvio Danese

  • September 12, 2024

  • 0 min

Share

Top Institutions in Gastroenterology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Gastroenterology
    • Inflammatory Bowel Disease
    • Clinical Research

  • #2

    Mount Sinai Health System
    Mount Sinai Health System

    New York, NY

    Key Differentiators

    • Gastroenterology
    • Inflammatory Bowel Disease
    • Translational Medicine

  • #3

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Gastroenterology
    • Inflammatory Bowel Disease
    • Clinical Trials

  • #4

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Gastroenterology
    • Inflammatory Bowel Disease
    • Advanced Therapeutics

  • #5

    Mount Carmel Health System
    Mount Carmel Health System

    Columbus, OH

    Key Differentiators

    • Gastroenterology
    • Inflammatory Bowel Disease

Original Source(s)

Prevalence, Characteristics, Management, and Outcomes of Difficult-to-Treat Inflammatory Bowel Disease

  • by Tommaso Lorenzo Parigi, Luca Massimino, Alfredo Carini, Roberto Gabbiadini, Peter Bertoli, Mariangela Allocca, Cristina Bezzio, Arianna Dal Buono, Ferdinando D’Amico, Federica Furfaro, Laura Loy, Alessandra Zilli, Federica Ungaro, Vipul Jairath, Laurent Peyrin-Biroulet, Alessandro Armuzzi, Silvio Danese

  • September 12, 2024

Related Content

Mortality trends from colorectal pathologies in the United States (1999–2020): a retrospective cohort study using CDC WONDER

Urologic malignancy risk with chronic tumor necrosis factor-alpha inhibitor (TNF-I) exposure: a multicenter, retrospective cohort study

Evaluation of Tacrolimus in Ulcerative Colitis: A Retrospective Analysis of Factors Influencing Remission Induction and Maintenance